First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Advertisement
Advertisement
Trending on OncLive
1
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
2
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
AI-Assisted Scoping Review of Code Sharing in Clinical Prediction Model Research
5